Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CETP | P11597 | 2/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642061 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL2709571 | 0.93 | HTT (0.51) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL204159 | 0.88 | KMT2A (0.49) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL204433 | 0.87 | BCHE (0.47) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL2682720 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAHPGDHSD17B10 | |
| SCHEMBL202175 | 0.85 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPK1LMNAHTT | |
| SCHEMBL22336416 | 0.83 | POLB (0.53) | ALDH1A1KDM4ETSHRGAAHPGD | |
| SCHEMBL20564258 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KDM4EGLALMNAHTT | |
| SCHEMBL2709340 | 0.82 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAHTTPOLB | |
| SCHEMBL6500635 | 0.82 | EP300 (0.57) | ALDH1A1KDM4ETSHRGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| EP-4291569-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | Duke University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2023-03-23 | — | — | US | disclosed |
| EP-3222621-B1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND AND ITS MEDICAL USE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| WO-2022173940-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | DUKE UNIVERSITY (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20210163477-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LIMITED (HK) | 2021-06-03 | — | — | US | disclosed |
| US-10954239-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | CANWELL BIOTECH LIMITED (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20210038713-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-02-11 | — | — | US | disclosed |
| EP-2606047-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M Innovative Properties Company (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012167081-A1 | HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012167088-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012024284-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1789042-A4 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1789042-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954239-B2 | Imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof | TLR8, TLR7, TLR1 | ALDH1A1 3120/4885KDM4E 1501/4885TSHR 2095/4885 |
| US-20230090437-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IRF3, IFNG, STING1 | ALDH1A1 4529/4885KDM4E 137/4885TSHR 3207/4885 |
| US-11524071-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IFNG, IRF3, STING1 | ALDH1A1 4614/4885KDM4E 364/4885TSHR 3820/4885 |
| US-20210038713-A1 | LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS | IFNG, IRF3, STING1 | ALDH1A1 4614/4885KDM4E 364/4885TSHR 3820/4885 |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | IL2, IL4, IRF3 | ALDH1A1 1123/4885KDM4E 2441/4885TSHR 629/4885 |
| US-12201688-B2 | Lipidated immune response modifier compound compositions, formulations, and methods | IRF3, IFNG, STING1 | ALDH1A1 4529/4885KDM4E 137/4885TSHR 3207/4885 |
| US-20240252617-A1 | CORONAVIRUS SPIKE PROTEIN DESIGNS, COMPOSITIONS AND METHODS FOR THEIR USE | SARS1, CD14, ACE2 | ALDH1A1 4877/4885KDM4E 4313/4885TSHR 4452/4885 |
| US-20210163477-A1 | IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | TLR8, TLR7, TLR1 | ALDH1A1 3120/4885KDM4E 1501/4885TSHR 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.